Human IL-1β ELISpot Set

Product Specifications

Catalogue N°

856.101.001 - 1 x 96 Discovery (plate not included)
856.101.001P - 1 x 96 Discovery (non-sterile plate)
856.101.001S - 1 x 96 Discovery (sterile plate)
856.101.005 - 5 x 96 (plates not included)
856.101.005P - 5 x 96 (non-sterile plates)
856.101.005S - 5 x 96 (sterile plates)
856.101.010 - 10 x 96 (plates not included)
856.101.010P - 10 x 96 (non-sterile plates)
856.101.010S - 10 x 96 (sterile plates)
856.101.015 - 15 x 96 (plates not included)
856.101.015P - 15 x 96 (non-sterile plates)
856.101.015S - 15 x 96 (sterile plates)
856.101.020 - 20 x 96 (plates not included)
856.101.020P - 20 x 96 (non-sterile plates)
856.101.020S - 20 x 96 (sterile plates)

Target species

Human

Specificity

Recognizes natural (pro and mature) human IL-1b

Incubation

3h after cell stimulation

Cross Reaction

No cross reactivity with other human cytokines

Kit Content

Diaclone ELISpot Sets include capture and detection antibodies, Streptavidin - Alkaline Phosphatase conjugated, BSA, BCIP/NTB and blocking reagent.

Additional Information

Spots read visually or with reader

Synonym

IL-1b

IL-1beta

• Related products

BACKGROUND

Interleukin-1 Beta (IL-1b) is a member of the interleukin-1 family. This family contains three structurally related polypeptides. The first two are IL-1a and IL-1b, each of which has a broad spectrum of both beneficial and harmful biologic actions, and the third is IL-1-receptor antagonist, which inhibits the activities of interleukin-1.

IL-1a and b present approximately 25% homology at the amino acid level, but the difference is in their tri dimensional structure. Two distinct receptor types have been isolated, that bind both forms. IL-1b is synthesized as a large precursor, with a molecular weight of 31 kDa. The molecular weight of the mature form is 17.5 kDa. Unlike IL-1a, the IL-1b precursor shows little or no biological activity in comparison to the mature form.

IL-1 is primarily an inflammatory cytokine. It belongs to a group of cytokines with overlapping biologic properties (TNFa and IL-6). IL-1, TNF and IL-6 share the ability to stimulate T and B lymphocytes, increase cell proliferation, and initiate or suppress gene expression for several proteins exerting their effects by binding to specific receptors.

IL-1 (a and b) have similar biological properties, among them, the ability to induce fever, sleep, anorexia and hypotension. IL-1 stimulates the release of pituitary hormones, increases the synthesis of collagenases, resulting in the destruction of cartilage, and stimulates the production of prostaglandins, leading to decrease in the pain threshold. In addition, IL-1 has some host defence properties. However, whereas IL-1b is a secreted cytokine, IL-1a is predominantly a cell-associated cytokine. IL-1 has also been implicated in the destruction of beta cells of the islets of Langerhans, the growth of myelogenous leukaemia cells, and the development of atherosclerotic plaques. It is described in several diseases: sepsis syndrome, rheumatoid arthritis, inflammatory Bowel disease, acute and chronic myelogenous leukaemia, insulin dependent diabetes mellitus and arthrosclerosis.

Version 8 - 07.19

For research use only

For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.